Clinical Trial Update: Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and effects of SLx-4090 after 14 days of dosing in subjects with high triglycerides has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• SLx-4090 (SLx-4090)

Snippet

Sponsor: Response Pharmaceuticals | Conditions: Hypertriglyceridemia | Phase 2 | Status: COMPLETED